TG Therapeutics | TGTX - Cost Of Sales


TG Therapeutics reported $33.51M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alaunos Therapeutics USD 0 18K Sep/2024
Amgen USD 1.6B 187M Mar/2026
Ardelyx USD 10.85M 6.87M Dec/2025
Bayer EUR 5.23B 731M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Corcept Therapeutics USD 2.88M 338K Mar/2026
Curis USD 314K 9.96M Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
Infinity Pharmaceuticals USD 352K 89K Jun/2023
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Novartis USD 3.46B 83M Mar/2026
Novavax USD 22.1M 608K Dec/2025
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
TG Therapeutics USD 33.51M 4.63M Mar/2026
Verastem USD 2.89M 2.88M Dec/2025
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026